57 related articles for article (PubMed ID: 9102869)
1. [The effect of alphacalcidol on calcium and phosphate metabolism in patients treated with hemodialysis].
Veljković S; Raicević R; Cukaranović R; Ralenković S; Stojanović M; Kostić S; Djordjević V; Radenković M
Srp Arh Celok Lek; 1996; 124 Suppl 1():117-8. PubMed ID: 9102869
[TBL] [Abstract][Full Text] [Related]
2. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
[TBL] [Abstract][Full Text] [Related]
3. [A long-term comparative study of calcitriol versus alphacalcidol in patients with secondary hyperparathyroidism on hemodialysis].
Arenas MD; Muray S; Amoedo ML; Egea JJ; Millán I; Gil MT
Nefrologia; 2006; 26(2):226-33. PubMed ID: 16808261
[TBL] [Abstract][Full Text] [Related]
4. [The effect of 1alpha-hydroxycholecalciferol on the abnormal calcium metabolism in hemodialysis patients.--Studies on patients showing low serum calcium and high alkaline phosphatase (author's transl)].
Asai K; Ohkura T; Sakamoto N; Kawahara H; Yamazaki C
Nihon Jinzo Gakkai Shi; 1978 Sep; 20(9):967-77. PubMed ID: 713173
[No Abstract] [Full Text] [Related]
5. [Pharmacotherapeutic assessment of antiosteoporotic properties of alpha-calcidol in chronic obstructive pulmonary disease].
Kochetkova EA; Volkova MV; Grigor'eva OIu; Gel'tser BI
Ter Arkh; 2006; 78(3):20-5. PubMed ID: 17019953
[TBL] [Abstract][Full Text] [Related]
6. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
[TBL] [Abstract][Full Text] [Related]
7. [The influence of short-term magnesium carbonate treatment on calcium-phosphorus balance in dialysis patients].
Zwiech R; Dryja P; Łacina D; Króliczak V; Chrul S; Kacprzyk F
Wiad Lek; 2011; 64(1):9-14. PubMed ID: 21812357
[TBL] [Abstract][Full Text] [Related]
8. [Alphacalcidol in the treatment of osteopenic syndrome in patients with bronchial asthma].
Kochetkova EA; Gel'tser BI
Ter Arkh; 2002; 74(3):32-5. PubMed ID: 11980117
[TBL] [Abstract][Full Text] [Related]
9. [Clinical estimation of 1-alpha-hydroxycholecalciferol in treatment of patients with chronic renal failure].
Chodorowski Z; Rutkowski B; Wielgosz A; Chamienia A; Sulima-Gillow A; Manitius A
Pol Tyg Lek; 1992 Dec 7-14; 47(49-50):1093-5. PubMed ID: 1305733
[TBL] [Abstract][Full Text] [Related]
10. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of metabolic effects of intravenously given alpha-calcidol in patients with chronic renal failure.
Lind L; Lithell H; Wengle B; Wrege U; Ljunghall S
Scand J Urol Nephrol; 1988; 22(3):219-22. PubMed ID: 3187441
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
[TBL] [Abstract][Full Text] [Related]
14. [Changes of calcium-phosphorus metabolism in patients with chronic renal failure on hemodialysis treatment].
Pérez Ruilópez MA; Damiano Rivero A; Herrerías Echabe JM; Garrido Peralta M
Rev Iber Endocrinol; 1976; 23(138):535-55. PubMed ID: 1013577
[TBL] [Abstract][Full Text] [Related]
15. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients.
Fiedler R; Deuber HJ; Langer T; Osten B; Mohan S; Jehle PM
Nephron Clin Pract; 2004; 96(1):c3-9. PubMed ID: 14752247
[TBL] [Abstract][Full Text] [Related]
16. Calcium set point progressively worsens in hemodialysis patients despite conventional oral 1-alpha hydroxycholecalciferol supplementation.
Ali AA; Varghese Z; Moorhead JF; Baillod RA; Sweny P
Clin Nephrol; 1993 Apr; 39(4):205-9. PubMed ID: 8491050
[TBL] [Abstract][Full Text] [Related]
17. Association of conjunctival and corneal calcification with vascular calcification in dialysis patients.
Seyahi N; Altiparmak MR; Kahveci A; Yetik H; Kanberoglu K; Serdengecti K; Ataman R; Erek E
Am J Kidney Dis; 2005 Mar; 45(3):550-6. PubMed ID: 15754277
[TBL] [Abstract][Full Text] [Related]
18. Marked improvement in bone metabolism parameters after increasing the dialysate calcium concentration from 2.5 to 3 mEq/L in nonhypercalcemic hemodialysis patients.
Molina Vila P; Sánchez Pérez P; Garrigós Almerich E; Peris Domingo A
Hemodial Int; 2008 Jan; 12(1):73-9. PubMed ID: 18271845
[TBL] [Abstract][Full Text] [Related]
19. Conjunctival and corneal calcification and bone metabolism in hemodialysis patients.
Tokuyama T; Ikeda T; Sato K; Mimura O; Morita A; Tabata T
Am J Kidney Dis; 2002 Feb; 39(2):291-6. PubMed ID: 11840369
[TBL] [Abstract][Full Text] [Related]
20. Intravenous alfacalcidol once weekly suppresses parathyroid hormone in hemodialysis patients.
Al-Hilali N; Al-Humoud H; Al-Helal B; Al-Azmi M; Al-Kandari NH; Johny KV
Ther Apher Dial; 2008 Apr; 12(2):137-42. PubMed ID: 18387162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
